Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells.
CD4+ T cell
CMS
adjuvant
antigen presenting cell (APC)
cytokines
dendritic cells
human
oil-in-water emulsion
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
11
2022
accepted:
05
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
We retrospectively analyzed the immunopotentiating mechanism of an oil-in-water (O/W) emulsion-based vaccine adjuvant LiteVax™ Adjuvant (LVA) that contains CMS (Maltose 4'-monosulphate 1,2,3,6,2',3',6'-heptadecanoic acid ester), squalane, Tween 80 in phosphate buffered saline. Despite being effective in animal models, the immunological mechanisms by which LVA exerts adjuvant function are not known. As dendritic cells (DC) are key for initiating and propagating the immune response, we have investigated the effect of LVA and of its components on the DC function. We show that CMS but not LVA significantly enhances the expression of DC activation-associated markers, cytokine secretion, and CD4
Identifiants
pubmed: 36700217
doi: 10.3389/fimmu.2022.1086752
pmc: PMC9868768
doi:
Substances chimiques
Adjuvants, Vaccine
0
Emulsions
0
Adjuvants, Immunologic
0
Adjuvants, Pharmaceutic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086752Informations de copyright
Copyright © 2023 Bonam, Platenburg and Bayry.
Déclaration de conflit d'intérêts
PP is one of the founders and owners of LiteVax BV, the company that holds IP related to CMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Appl Toxicol. 1999 May-Jun;19(3):163-5
pubmed: 10362266
Nat Rev Drug Discov. 2021 Jun;20(6):454-475
pubmed: 33824489
Front Immunol. 2022 May 06;13:865507
pubmed: 35603193
Trends Pharmacol Sci. 2017 Sep;38(9):771-793
pubmed: 28668223
Vaccine. 2017 May 31;35(24):3249-3255
pubmed: 28479181
Vaccines (Basel). 2021 Sep 24;9(10):
pubmed: 34696180
Cell Mol Immunol. 2021 May;18(5):1197-1210
pubmed: 33762685
mBio. 2021 Dec 21;12(6):e0282421
pubmed: 34781737
Vaccine. 2004 Dec 21;23(6):743-54
pubmed: 15542198
Front Immunol. 2020 Oct 30;11:599587
pubmed: 33193454
Front Immunol. 2022 Aug 01;13:940047
pubmed: 35979365
Front Immunol. 2021 Jan 14;11:606805
pubmed: 33519816
NPJ Vaccines. 2021 Dec 21;6(1):158
pubmed: 34934069
Nat Rev Chem. 2021;5(3):197-216
pubmed: 33521324
Front Immunol. 2018 Dec 13;9:2874
pubmed: 30619259
Front Immunol. 2022 Aug 04;13:941474
pubmed: 35990665
Vaccine. 2006 Apr 12;24 Suppl 2:S2-81-2
pubmed: 16823938